PubRank

Augusto Villanueva

Author PubWeight™ 73.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 9.20
2 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008 5.78
3 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
4 Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 3.77
5 A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009 3.44
6 Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009 2.79
7 Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010 2.46
8 Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 2.42
9 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
10 Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011 2.39
11 A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013 2.37
12 A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006 2.32
13 Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013 2.13
14 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
15 Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010 1.68
16 IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 1.66
17 Experimental models of hepatocellular carcinoma. J Hepatol 2008 1.61
18 Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009 1.52
19 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012 1.44
20 Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012 1.32
21 Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012 1.26
22 Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008 1.21
23 Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009 1.17
24 Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 2011 1.07
25 Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 2012 1.02
26 Signaling pathways in hepatocellular carcinoma. Oncology 2011 0.98
27 Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 2012 0.88
28 Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015 0.88
29 Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol 2008 0.85
30 Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology 2012 0.85
31 Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011 0.84
32 miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology 2010 0.84
33 Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol 2013 0.84
34 Why men are at higher risk for hepatocellular carcinoma? J Hepatol 2012 0.82
35 Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl 2006 0.82
36 [Cell biology and genetics in liver cancer]. Gastroenterol Hepatol 2007 0.80
37 microRNAs: new ways to block tumor angiogenesis? J Hepatol 2012 0.79
38 Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. Eur J Gastroenterol Hepatol 2006 0.75
39 Transplantation for hepatocellular carcinoma--worth waiting for? Liver Transpl 2014 0.75
40 Genomic tracing of the elusive liver cancer ancestor. J Hepatol 2010 0.75
41 Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. J Hepatol 2011 0.75
42 [Genomic prognostic markers in hepatocellular carcinoma]. Gastroenterol Hepatol 2011 0.75
43 Genetically engineered mouse models: future tools to predict clinical trial results in oncology? Future Oncol 2013 0.75